{
    "clinical_study": {
        "@rank": "95648", 
        "arm_group": [
            {
                "arm_group_label": "Healthy controls", 
                "arm_group_type": "Other", 
                "description": "Healthy controls receiving 1000 mg metformin twice daily for 3 months"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Metformin \"Sandoz\", 1000 mg twice daily for 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Background: Metformin treatment has beneficial effects on both glucose and lipid metabolism.\n      Whereas there is general agreement that the blood glucose lowering effect of metformin\n      results from inhibition of hepatic gluconeogenesis, it is less clear exactly how the drug\n      lowers blood triglyceride concentration. There are indications that it enhances hepatic free\n      fatty acid (FFA) oxidation thus diminishing substrate for reesterification and resecretion\n      as very-low-density-lipoprotein (VLDL) triglycerides (TG). However, the liver is not easily\n      accessible for sampling in humans and data on the clinical effects of metformin in the liver\n      are therefore lacking. This may change due to the increasing use of the positron emission\n      tomography (PET) technique. Using PET isotopes (11C or 18F) coupled to either palmitate or a\n      fatty acid analogue, it is possible to non-invasively measure hepatic fatty acid handling.\n\n      Aim: To determine how 3 months metformin treatment (1000 mg twice daily) affects hepatic\n      lipid metabolism in patients with newly diagnosed type 2 diabetes.\n\n      Design: Randomized, placebo controlled, double-blind parallel study with patients receiving\n      either metformin or placebo. A control group of BMI and age-matched healthy controls will\n      receive metformin for 3 months.\n\n      Hypothesis: Metformin lowers VLDL-TG secretion and circulating triglycerides by increasing\n      hepatic fatty acid oxidation"
        }, 
        "brief_title": "Effects of Metformin on Hepatic FFA Metabolism", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Dyslipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed type 2 diabetes (>3 and <12 months)\n\n          -  Age 50-70 years\n\n          -  BMI<40\n\n        Exclusion Criteria:\n\n          -  Metformin treatment >6 months\n\n          -  NASH (non alcoholic steatohepatitis)\n\n          -  Cancer\n\n          -  Anemia\n\n          -  HbA1C>8.5 %\n\n          -  Chronic or acute pancreatitis\n\n          -  Alcohol or medicine abuse\n\n          -  Allergy towards metformin\n\n          -  Claustrophobia\n\n          -  Severe obesity (weight >130 kilogram)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729156", 
            "org_study_id": "C11palmitatMetformin"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Healthy controls", 
                    "Metformin"
                ], 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Metformin \"Sandoz\" 500 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "Hepatic fatty acid oxidation", 
            "Dyslipidemia", 
            "Metformin"
        ], 
        "lastchanged_date": "November 26, 2012", 
        "number_of_arms": "3", 
        "official_title": "Effects of Metformin on Hepatic Free Fatty Acid Metabolism in Patients Diagnosed With Type 2 Diabetes: A C11 PET Study", 
        "overall_contact": {
            "email": "lars.christian.gormsen@ki.au.dk", 
            "last_name": "Lars C Gormsen, MD PhD", 
            "phone": "+4578456205"
        }, 
        "overall_official": {
            "affiliation": "Aarhus University Hospital", 
            "last_name": "Lars C Gormsen, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Health and Medicines Authority", 
                "Denmark: The Central Denmark Region Committees on Health Research Ethics"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Hepatic fatty acid oxidation assessed by dynamic C11-palmitate PET", 
                "measure": "Hepatic fatty acid oxidation", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }, 
            {
                "description": "Hepatic fatty acid reesterification assessed by C11-palmitate PET", 
                "measure": "Hepatic fatty acid reesterification", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }, 
            {
                "description": "Hepatic fatty acid uptake assessed by C11-palmitate PET", 
                "measure": "Hepatic fatty acid uptake", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }, 
            {
                "description": "Hepatic VLDL-TG secretion assessed by [1-14C] VLDL tracer", 
                "measure": "VLDL-TG secretion", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729156"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aarhus University Hospital", 
            "investigator_full_name": "Lars Christian Gormsen", 
            "investigator_title": "Senior Registrar, MD PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Weight loss after metformin treatment", 
                "measure": "Weight loss", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }, 
            {
                "description": "Fatty acid turnover assessed as whole body C11-palmitate turnover", 
                "measure": "Fatty acid turnover", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }, 
            {
                "description": "VLDL-TG oxidation assessed by 14C carbon dioxide (CO2) in exhaled breath", 
                "measure": "VLDL-TG oxidation", 
                "safety_issue": "No", 
                "time_frame": "06/01/2015"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lars Christian Gormsen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}